CABA Quote, Financials, Valuation and Earnings

ACADIA Pharmaceuticals has a net margin of -- compared to Cabaletta Bio's net margin of 7.77%. Cabaletta Bio's return on equity of -- beat ACADIA Pharmaceuticals's return on equity of 37.45%.

Cabaletta Bio has a consensus price target of $15.67, signalling upside risk potential of 827.02%. On the other hand ACADIA Pharmaceuticals has an analysts' consensus of $28.74 which suggests that it could grow by 27.44%. Given that Cabaletta Bio has higher upside potential than ACADIA Pharmaceuticals, analysts believe Cabaletta Bio is more attractive than ACADIA Pharmaceuticals.

Cabaletta Bio has a beta of 2.705, which suggesting that the stock is 170.496% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals has a beta of 0.641, suggesting its less volatile than the S&P 500 by 35.902%.

Cabaletta Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cabaletta Bio pays -- of its earnings as a dividend. ACADIA Pharmaceuticals pays out -- of its earnings as a dividend.

Cabaletta Bio quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals quarterly revenues of $244.3M. Cabaletta Bio's net income of -$35.9M is lower than ACADIA Pharmaceuticals's net income of $19M. Notably, Cabaletta Bio's price-to-earnings ratio is -- while ACADIA Pharmaceuticals's PE ratio is 16.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cabaletta Bio is -- versus 3.77x for ACADIA Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

BioMarin Pharmaceutical has a net margin of -- compared to Cabaletta Bio's net margin of 24.92%. Cabaletta Bio's return on equity of -- beat BioMarin Pharmaceutical's return on equity of 9.62%.

Cabaletta Bio has a consensus price target of $15.67, signalling upside risk potential of 827.02%. On the other hand BioMarin Pharmaceutical has an analysts' consensus of $95.69 which suggests that it could grow by 63.89%. Given that Cabaletta Bio has higher upside potential than BioMarin Pharmaceutical, analysts believe Cabaletta Bio is more attractive than BioMarin Pharmaceutical.

Cabaletta Bio has a beta of 2.705, which suggesting that the stock is 170.496% more volatile than S&P 500. In comparison BioMarin Pharmaceutical has a beta of 0.168, suggesting its less volatile than the S&P 500 by 83.229%.

Cabaletta Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cabaletta Bio pays -- of its earnings as a dividend. BioMarin Pharmaceutical pays out -- of its earnings as a dividend.

Cabaletta Bio quarterly revenues are --, which are smaller than BioMarin Pharmaceutical quarterly revenues of $745.1M. Cabaletta Bio's net income of -$35.9M is lower than BioMarin Pharmaceutical's net income of $185.7M. Notably, Cabaletta Bio's price-to-earnings ratio is -- while BioMarin Pharmaceutical's PE ratio is 21.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cabaletta Bio is -- versus 3.91x for BioMarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Cabaletta Bio's net margin of -49.65%. Cabaletta Bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Cabaletta Bio has a consensus price target of $15.67, signalling upside risk potential of 827.02%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Cabaletta Bio has higher upside potential than NovaBay Pharmaceuticals, analysts believe Cabaletta Bio is more attractive than NovaBay Pharmaceuticals.

Cabaletta Bio has a beta of 2.705, which suggesting that the stock is 170.496% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Cabaletta Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cabaletta Bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Cabaletta Bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cabaletta Bio's net income of -$35.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Cabaletta Bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cabaletta Bio is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Cabaletta Bio's net margin of --. Cabaletta Bio's return on equity of -- beat Theriva Biologics's return on equity of --.

Cabaletta Bio has a consensus price target of $15.67, signalling upside risk potential of 827.02%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Cabaletta Bio, analysts believe Theriva Biologics is more attractive than Cabaletta Bio.

Cabaletta Bio has a beta of 2.705, which suggesting that the stock is 170.496% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Cabaletta Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cabaletta Bio pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Cabaletta Bio quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Cabaletta Bio's net income of -$35.9M is lower than Theriva Biologics's net income of -$4.3M. Notably, Cabaletta Bio's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cabaletta Bio is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.